IDEAYA Biosciences, Inc.
IDYA
$30.24
$0.391.31%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 214.83M | 7.00M | 7.00M | 7.00M | 3.92M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 214.83M | 7.00M | 7.00M | 7.00M | 3.92M |
| Cost of Revenue | 368.29M | 342.45M | 322.75M | 294.67M | 193.26M |
| Gross Profit | -153.45M | -335.45M | -315.75M | -287.67M | -189.34M |
| SG&A Expenses | 55.43M | 48.78M | 44.59M | 39.30M | 35.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 423.72M | 391.23M | 367.35M | 333.98M | 228.68M |
| Operating Income | -208.88M | -384.23M | -360.35M | -326.98M | -224.75M |
| Income Before Tax | -160.74M | -331.80M | -307.08M | -274.48M | -178.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -160.74 | -331.80 | -307.08 | -274.48 | -178.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -160.74M | -331.80M | -307.08M | -274.48M | -178.12M |
| EBIT | -208.88M | -384.23M | -360.35M | -326.98M | -224.75M |
| EBITDA | -206.33M | -381.76M | -357.98M | -324.59M | -222.31M |
| EPS Basic | -1.84 | -3.79 | -3.59 | -3.30 | -2.33 |
| Normalized Basic EPS | -1.31 | -2.53 | -2.41 | -2.23 | -1.56 |
| EPS Diluted | -1.85 | -3.79 | -3.59 | -3.30 | -2.33 |
| Normalized Diluted EPS | -1.33 | -2.53 | -2.41 | -2.23 | -1.56 |
| Average Basic Shares Outstanding | 352.70M | 350.36M | 339.85M | 326.60M | 304.51M |
| Average Diluted Shares Outstanding | 353.86M | 350.36M | 339.85M | 326.60M | 304.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |